| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 419,665 | 61,861 | ||
| Marketable securities, available-for-sale | 282,298 | 486,316 | ||
| Accounts receivable, net and contract assets | 346,035 | 316,339 | ||
| Inventories | 185,796 | 181,505 | ||
| Prepaid expenses and other current assets | 94,955 | 76,652 | ||
| Total current assets | 1,328,749 | 1,122,673 | ||
| Property and equipment, gross | 71,634 | - | ||
| Accumulated depreciation and amortization | 31,059 | - | ||
| Subtotal | 40,575 | - | ||
| Right of use of assets | 30,845 | - | ||
| Property and equipment, net | 71,420 | 71,520 | ||
| Prepaid expenses and other assets | 55,698 | 56,371 | ||
| Goodwill | 416,821 | 416,821 | ||
| Gross carrying value | 538,200 | - | ||
| Accumulated amortization | 238,356 | - | ||
| Total | 299,844 | - | ||
| Atrs-1902 (ipr&d) | 48,700 | - | ||
| Intangible assets, net | 348,544 | 366,306 | ||
| Deferred tax assets, net | 0 | 20,208 | ||
| Total assets | 2,221,232 | 2,053,899 | ||
| Accounts payable | 15,360 | 18,691 | ||
| Accrued expenses | 111,183 | 115,591 | ||
| Current portion of long-term debt, net | 710,685 | - | ||
| Total current liabilities | 837,228 | 134,282 | ||
| Long-term debt, net | 800,072 | 1,509,100 | ||
| Other long-term liabilities | 71,799 | 77,769 | ||
| Deferred tax liabilities, net | 8,218 | - | ||
| Total liabilities | 1,717,317 | 1,721,151 | ||
| Common stock - 0.001 par value 300,000 shares authorized 117,523 and 123,138 shares issued and outstanding as of september30, 2025 and december31, 2024, respectively | 118 | 118 | ||
| Additional paid-in capital | 23,909 | 0 | ||
| Accumulated other comprehensive (loss) income | -22,258 | -28,403 | ||
| Retained earnings | 502,146 | 361,033 | ||
| Total stockholders equity | 503,915 | 332,748 | ||
| Total liabilities and stockholders equity | 2,221,232 | 2,053,899 | ||
HALOZYME THERAPEUTICS, INC. (HALO)
HALOZYME THERAPEUTICS, INC. (HALO)